Compounds > anecortave
Page last updated: 2024-11-11

anecortave

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Anecortave: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6442411
CHEBI ID183949
SCHEMBL ID14917092
MeSH IDM0576742
PubMed CID7074810
CHEMBL ID2348782
CHEBI ID177649
SCHEMBL ID722748
MeSH IDM0576742

Synonyms (43)

Synonym
cid 6442411
94079-81-9
[6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
poliumoside
CHEBI:183949
HY-N0033
SCHEMBL14917092
AC-34320
6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-4-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-2-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
AS-75175
AKOS037647890
(8s,10s,13s,14s,17r)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one
10184-70-0
anecortave
CHEBI:177649
al-4940
17,21-dihydroxypregna-4,9(11)-diene-3,20-dione
al 4940
anecortave [usan]
r5y8o51589 ,
unii-r5y8o51589
anecortave (usan)
anecortave [who-dd]
pregna-4,9(11)-diene-3,20-dione, 17,21-dihydroxy-
al4940
anecortave desacetate
CHEMBL2348782
17alpha,21-dihydroxy-pregna-4,9(11)-diene-3,20-dione
BCFCRXOJOFDUMZ-ONKRVSLGSA-N
17,21-dihydroxy-4,9(11) pregnadiene3,20-dione
17,21-dihydroxy-4,9(11)-pregnadiene-3,20-dione
17a,21-dihydroxy-pregna-4,9(11)-diene-3,20-dione
SCHEMBL722748
DTXSID70144268
21-desacetyl anecortave
J-000504
17-desacetyl anecortave
DB12081
Q27287834
17,21-dihydroxy-pregna-4,9(11)-diene-3,20-dione
HY-116098
CS-0063963
AKOS040746569

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Poliumoside is also regarded as the main active component of Callicarpa kwangtungensis Chun (CK), though its oral bioavailability in rat is extremely low (0."( Identification of poliumoside metabolites in rat plasma, urine, bile, and intestinal bacteria with UPLC/Q-TOF-MS.
Lu, DY; Ma, ZG; Qian, H; Wang, H; Wu, BJ; Yu, FJ; Zhang, XW, 2018)		0.48
"42 h (dogs), and bioavailability of 74."( VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
Damsker, JM; Hoffman, EP; McCall, JM; Nagaraju, K; Reeves, EKM, 2013)		0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
oligosaccharideA compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues.
21-hydroxy steroid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID740556Induction of glucocorticoid receptor nuclear translocation in mouse C2C12 cells at 1 x 10'-5 to 1.69 x 10'-10 M by chemiluminescence assay relative to control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
AID740557Inhibition of TNFalpha-induced NFkappaB activation in mouse C2C12 cells incubated for 24 hrs prior to TNFalpha induction measured after 24 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (30.77)18.2507
2000's0 (0.00)29.6817
2010's8 (61.54)24.3611
2020's1 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.90 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index28.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00788541]Phase 2197 participants (Actual)Interventional2008-12-31Terminated(stopped due to Project cancellation)
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration. [NCT00051129]Phase 3291 participants (Actual)Interventional2007-01-31Completed
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma [NCT00451152]Phase 289 participants (Actual)Interventional2007-03-31Completed
Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Singaporean Patients at Risk for Progressing to Exudative Age-Related Macular Degeneration (AMD) [NCT00333216]Phase 324 participants (Actual)Interventional2005-05-31Terminated(stopped due to Lack of efficacy)
[NCT00307398]Phase 32,596 participants (Actual)Interventional2004-03-31Terminated(stopped due to Management decision)
A Study of the Safety and Efficacy of Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation [NCT00315640]Phase 270 participants (Actual)Interventional2005-12-31Completed
An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg in Patients With Subfoveal Exudative Age-Related Macular Degeneration (AMD) [NCT00065728]Phase 3111 participants (Actual)Interventional2003-06-30Terminated(stopped due to Management decision)
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension [NCT00691717]Phase 2/Phase 3201 participants (Actual)Interventional2008-06-30Completed
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma [NCT00320203]Phase 286 participants (Actual)Interventional2006-03-31Completed
[NCT00211484]Phase 25 participants (Actual)Interventional2003-05-31Completed
Compassionate Use of Anecortave Acetate: Clinical Protocol for the Treatment of Corticosteroid-induced Intraocular Pressure (IOP) Increases After Corneal Transplantation [NCT00884039]7 participants (Actual)Interventional2009-05-31Terminated(stopped due to Preliminary data analysis showed insufficient efficacy to justify continuation.)
[NCT00705770]Phase 2/Phase 30 participants (Actual)Interventional2008-05-31Withdrawn(stopped due to Change in study design)
[NCT00211328]Phase 25 participants (Actual)Interventional2002-03-31Completed
[NCT00211406]Phase 10 participants InterventionalTerminated
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension (15mg.). [NCT00211471]Phase 20 participants (Actual)Interventional2002-03-31Terminated(stopped due to poor enrollment)
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal Choroidal Neovascularization Due to Exudative Age-related Macular Degeneration [NCT00058994]Phase 30 participants Interventional2003-03-31Completed
Prevention of Steroid-induced Glaucoma Using Anecortave Acetate [NCT00570479]Phase 112 participants (Actual)Interventional2006-09-30Completed
[NCT00211367]Phase 22 participants (Actual)Interventional2004-04-30Terminated(stopped due to poor enrollment)
Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD) [NCT00211419]Phase 10 participants InterventionalCompleted
Treatment of Age-Related Macular Degeneration With Open-label Anecortave Acetate Sterile Suspension (15mg) Following Failed Treatment With Photodynamic Therapy With Visudyne [NCT00211458]Phase 20 participants Interventional2005-09-30Completed
Clinical Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate Sterile Suspension [NCT00349739]0 participants Expanded Access2003-01-31No longer available
Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate [NCT00489840]Phase 1/Phase 25 participants (Actual)Interventional2007-05-31Completed
Anecortave Acetate Versus Placebo in AMD Patients Following PDT [NCT00346866]Phase 2136 participants Interventional2000-05-31Completed
[NCT00346957]Phase 2128 participants (Actual)Interventional1999-04-30Completed
Anterior Juxtascleral Depot of Anecortave Acetate: Intraocular Pressure Reduction in Glaucoma Patients [NCT00533962]30 participants (Actual)Interventional2007-08-31Active, not recruiting
[NCT00211315]Phase 24 participants (Actual)Interventional2002-03-31Completed
[NCT00211354]Phase 20 participants (Actual)Interventional2002-03-31Withdrawn(stopped due to No subjects enrolled)
[NCT00211432]Phase 24 participants (Actual)Interventional2008-04-30Completed
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD [NCT00041483]Phase 3530 participants (Actual)Interventional2002-06-30Completed
[NCT00332657]Phase 336 participants (Actual)Interventional2006-09-30Terminated(stopped due to Management Decision)
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative Age-Related Macular Degeneration (AMD) [NCT00299507]Phase 3240 participants (Actual)Interventional2005-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00884039 (1) [back to overview]Intraocular Pressure Within Normal Limits (<24 mm Hg)

Intraocular Pressure Within Normal Limits (<24 mm Hg)

Intraocular pressure was measured by Goldmann applanation tonometry. (NCT00884039)
Timeframe: 1 month

InterventionParticipants (Number)
30 mg Anecortave Acetate2
15 mg Anecortave Acetate1

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glucose, (beta-d)-isomer
beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.		2.4920D-glucopyranoseepitope;
mouse metabolite
glycosides
[no description available]		3.4770
forsythiaside
forsythiaside: RN given refers to (E)-isomer; structure given in first source; from the unripe fruit of Forsythia suspensa (qinglianquiao)		2.0810hydroxycinnamic acid
acteoside
acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.		2.4920catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
alyssonoside
alyssonoside: from Marrubium alysson; structure given in first source		2.110
isoacteoside
isoacteoside: a phenylethanoid glycoside isolated from Indian paintbrush (Verbenaceae) Castilleja linariaefolia; also in other plants; structure given in first source		2.110hydroxycinnamic acid
tubuloside b
tubuloside B: hepatoprotective agent isolated from Cistanche deserticola; structure in first source		2.110
2'-acetylacteoside
2'-acetylacteoside: hepatoprotective agent isolated from Cistanch deserticola; structure in first source		2.110
forsythoside b
forsythoside B: structure in first source		2.8330
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		31011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		2.081011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
anecortave acetate
anecortave acetate: derived from cortisone (11 OH replaced by 9-11 double bond)		4.0350organic molecular entity
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.7130
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		02.0810
Intraocular Pressure
The pressure of the fluids in the eye.		02.0810
Corneal Angiogenesis
[description not available]		01.9910
Corneal Neovascularization
New blood vessels originating from the corneal blood vessels and extending from the limbus into the adjacent CORNEAL STROMA. Neovascularization in the superficial and/or deep corneal stroma is a sequel to numerous inflammatory diseases of the ocular anterior segment, such as TRACHOMA, viral interstitial KERATITIS, microbial KERATOCONJUNCTIVITIS, and the immune response elicited by CORNEAL TRANSPLANTATION.		01.9910
B16 Melanoma
[description not available]		0210
Uveal Neoplasms
Tumors or cancer of the UVEA.		0210
Choroid Neovascularization
[description not available]		0210
Angiogenesis, Pathologic
[description not available]		0210